Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
The Journal.
00:00
Unexpected Leadership Changes at Novo Nordisk
This chapter explores the forced departure of Novo Nordisk's CEO after eight years, illuminating the company's pivotal role in insulin production and the success of its diabetes drug, Ozempic. It delves into the potential impact on the company's future direction and leadership stability.
Transcript
Play full episode
